Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

NARecruitingINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

July 23, 2025

Primary Completion Date

May 31, 2028

Study Completion Date

July 31, 2028

Conditions
Pulmonary HypertensionInterstitial Lung Disease (ILD)
Interventions
DEVICE

ECG-based AI Device - Results Returned to Investigator

An ECG-based AI device that predicts undiagnosed PH using data from a 12-lead ECG. Device results will be returned to the Investigators.

PROCEDURE

Echocardiogram and Right Heart Catheterization

Echocardiogram- an ultrasound study of the heart and Right Heart Catheterization- a procedure to measure pressures in the heart

DEVICE

ECG-based AI Device - Results Not Returned to Investigator

An ECG-based AI device that predicts undiagnosed PH using data from a 12-lead ECG. Device results will not be returned to the Investigators.

Trial Locations (11)

32803

RECRUITING

AdventHealth Orlando, Orlando

35205

RECRUITING

University of Alabama at Birmingham, Birmingham

40536

RECRUITING

University of Kentucky, Lexington

46202

RECRUITING

Indiana University Health Methodist Hospital, Indianapolis

55455

RECRUITING

University of Minnesota, Minneapolis

60612

RECRUITING

University of Illinois Health, Chicago

68124

RECRUITING

CHI Health Creighton University Medical Center - Bergan Mercy, Omaha

75246

RECRUITING

Baylor University Medical Center, Dallas

80206

RECRUITING

National Jewish Health, Denver

85013

RECRUITING

Dignity Health - St. Joseph's Hospital and Medical Center-Norton Thoracic Institute, Phoenix

48109-5360

RECRUITING

University of Michigan - Michigan Medicine, Ann Arbor

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

United Therapeutics

INDUSTRY

lead

Tempus AI

INDUSTRY